Menu
Start Screening

Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

Biochemical Analysis and Sensing Techniques LSD PTSD

1 paper

LSD for PTSD

Based on 16 papers

Research on psychedelics shows promise for treating PTSD, but most strong clinical results come from MDMA, not LSD. Studies and reviews suggest classic psychedelics like LSD can change brain circuits and may help people break out of stuck patterns. However, high-quality trials testing LSD for PTSD are few, and scientists still have many unanswered questions about how, when, and for whom it helps. In controlled research settings, psychedelic-assisted therapies have often been safe and helpful for some people. Still, the evidence specifically for LSD and PTSD is limited. Scientists warn we need bigger, more diverse trials and clearer measures of long-term benefits and risks before drawing firm conclusions.

Key findings

  • Most of the strongest clinical evidence for psychedelic treatment of PTSD comes from MDMA-assisted therapy, where larger trials showed big benefits. 15063 15078
  • There are far fewer high-quality clinical trials testing LSD specifically for PTSD than there are for MDMA or psilocybin. 15135 15085 15078
  • Classic psychedelics like LSD mainly act on the brain’s serotonin 2A receptor and often change perception and thinking during the experience. 15086 15050 15091
  • Lab and animal studies show classical psychedelics can boost neuroplasticity — meaning they help brain cells make new branches and connections — which might help therapy. 15050 15091
  • Human studies that measured blood BDNF, a protein sometimes used as a marker of brain plasticity, did not find clear increases after psychoplastogen drugs, so blood BDNF changes are not proven. 15129
  • Clinical trials done under medical supervision have generally reported favorable safety profiles, but that does not mean all risks are known. 15135 15087
  • Some psychedelics (for example, ibogaine) have serious physical risks such as heart problems, showing that safety differs across drugs. 15050 15085
  • Non-drug factors strongly shape outcomes: careful preparation, the therapy given during the session, and follow-up integration are important for both safety and benefit. 15065 15086 15063
  • Many trials are small and most study participants have been white, so we do not know if results apply to people of color or to larger, more varied populations. 15085 15095
  • Important open questions remain: whether the psychedelic experience itself is required for benefit, how long positive effects last, the best ways to deliver therapy, and long-term safety. 15078 15086 15091

Therapeutic mechanisms of psychedelics and entactogens

Boris D. Heifets, David E. Olson
Neuropsychopharmacology Summary & key facts 2023 59 citations

This paper reviews human and animal research on so-called psychedelics (like psilocybin and LSD) and entactogens (mainly MDMA). The authors say these drugs can produce fast improvements in mental health that sometimes last for months or longer. But we do not yet understand exactly how they work. Human studies point…

Biochemical Analysis and Sensing Techniques Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ketamine LSD
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.